GLPwatch

Epac is required for GLP-1R-mediated inhibition of oxidative stress and apoptosis in cardiomyocytes.

Mol Endocrinol · 2015

Last updated 2026-05-28

In lab tests, a GLP-1 drug called exendin-4 reduced harmful oxidative stress and cell damage in heart cells exposed to stress. The effects were linked to a protein called Epac, which helped increase protective enzymes and reduce cell death. Both Epac and another protein (PKA) were involved in these protective actions.

AI summary of the abstract below.

JournalMol Endocrinol, 2015
Citations60
Relative citation ratio2.22
NIH percentile77
Molecules
Conditions studied Heart Failure

Abstract

Although the cardioprotective effects of glucagon-like peptide-1 and its analogs have been reported, the exact mechanisms of the glucagon-like peptide-1 receptor (GLP-1R) signaling pathway in the heart are still unclear. Activation of the GLP-1R has been shown to increase cAMP levels, thus eliciting protein kinase A- and exchange protein activated by cAMP (Epac)-dependent signaling pathways in pancreatic β-cells. However, which pathway plays an important role in the antioxidant and antiapoptotic effects of GLP-1R activation in the heart is not known. In this study, we demonstrated that stimulation of GLP-1Rs with exendin-4 attenuated H2O2-induced reactive oxygen species production and increased the synthesis of antioxidant enzymes, catalase, glutathione peroxidase-1, and manganese superoxide dismutase that is dependent on Epac. Additionally, exendin-4 has an antiapoptotic effect by decreasing a number of apoptotic cells, inhibiting caspase-3 activity, and enhancing the expression of antiapoptotic protein B-cell lymphoma 2, which is mediated through both protein kinase A- and Epac-dependent pathways. These data indicate a critical role for Epac in GLP-1R-mediated cardioprotection.

Verbatim abstract via PubMed 25719403 ↗